Lior Dayan
Chief Executive Officer, CISRAM Medical Technology
Replay available
Sisram Med Ltd (OTC: SRAMF) Q2 2023 earnings conference call, held 2023-08-24. Replay captured from the company's public earnings webcast.

Chief Executive Officer, CISRAM Medical Technology
Analyst, JP Morgan
Analyst, China American Securities, Hong Kong
Chairman, CISRAM Medical Technology
Conference Participant
Hello, welcome to join the Cicero Medical Technology Annual Report in 2023 conference call. All attendees are muted now. Here we go with a disclaimer. This conference call is only open to CineLink's professional institutional investors or invited clients for the exchange of research views only. The content of conference doesn't stand for private investment opinions. Without the prior written permission of Simulink Securities, any institution or individual is strictly prohibited from disclosing the contents and relevant information of the conference in any form, share with others, download, spread, copy, edit, modify, interpret, and so on. We will resolve all the legal rights for those suspected of violating the above. Thank you for your understanding and support. There will be question and answer session after the guest finishes his speech. Now, let's welcome the host of CineLink to speak. Thank you. Good morning and welcome to CISREN Medical Earnings Call for the first half of year 2023. has a job in a pharmaceutical analyst from Sinalink Securities. Please note, this event is being recorded. I would now like to turn the call over to the RR team. Mary, please go ahead. Thank you, operator, and everyone for joining us today. Welcome to CISFIRM's earnings call. I would like to remind our listeners that certain information provided in this call may contain forward-looking statements. and changes in business, competitive, technological, regulatory, and other factors could cause actual results to differ materially from the forward-looking statements made today. Our historical results are not necessarily indicative of future performance. As such, we can give no assurance as to the accuracy of our forward-looking statements and assume no obligation to update them except as...